(NASDAQ: INKT) Mink Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Mink Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast INKT's revenue for 2027 to be $305,351,693, with the lowest INKT revenue forecast at $305,351,693, and the highest INKT revenue forecast at $305,351,693. On average, 1 Wall Street analysts forecast INKT's revenue for 2028 to be $2,442,813,542, with the lowest INKT revenue forecast at $2,442,813,542, and the highest INKT revenue forecast at $2,442,813,542.
In 2029, INKT is forecast to generate $3,580,942,579 in revenue, with the lowest revenue forecast at $3,580,942,579 and the highest revenue forecast at $3,580,942,579.